An analysis of FDA-approved drugs for infectious disease: antibacterial agents.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Drug Discovery Today

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.drudis.2014.07.005PMID 25043770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs.

  2014cited by this paper
• Platforms for antibiotic discovery

  2013cited by this paper
• Fidaxomicin for Clostridium difficile-Associated Diarrhoea

  2012cited by this paper
• The burden of disease and the changing task of medicine.

  2012cited by this paper
• Fidaxomicin for Clostridium difficile-associated diarrhoea: epidemiological method for estimation of warranted price.

  2012cited by this paper
• Combating antimicrobial resistance: policy recommendations to save lives.

  2011cited by this paper
• The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

  2008cited by this paper
• Cost‐Effectiveness of Telavancin versus Vancomycin for Treatment of Complicated Skin and Skin Structure Infections

  2008cited by this paper
• Sampling the Antibiotic Resistome

  2006cited by this paper
• Antibiotics in animal feeds--human and animal safety issues.

  1978cited by this paper
• Sulfanilamide: A Review

  1938cited by this paper
• Infection Control and Hospital Epidemiology Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the Prevention of Antimicrobial Resistance in Hospitals Shea Position Paper Infection Co

  year unknowncited by this paper

• Dual Redox Targeting by Pyrroloformamide A and Silver Ions Enhances Antibacterial and Anti-Biofilm Activity Against Carbapenem-Resistant Klebsiella pneumoniae

  2025cites this paper
• Innovative nanotechnology for infectious and inflammatory disease control: From diagnostics to therapeutics.

  2025cites this paper
• Decoding antibiotic resistance in Pseudomonas aeruginosa: Embracing innovative therapies beyond conventional antibiotics

  2025cites this paper
• Antibiotic–Adjuvants Abolish Resistance Conferred by the Staphylococcus aureus Erythromycin Resistance Methyltransferase in an Escherichia coli Model

  2025influential citation
• A peptide targeting outer membrane protein A of Acinetobacter baumannii exhibits antibacterial activity by reducing bacterial pathogenicity

  2024cites this paper
• Antibiotic Development: Lessons from the Past and Future Opportunities

  2024cites this paper
• Nanozybiotics: Advancing Antimicrobial Strategies Through Biomimetic Mechanisms

  2024cites this paper
• Applied physiology: gut microbiota and antimicrobial therapy

  2024cites this paper
• Steering the Microbiota-Gut-Brain Axis by Antibiotics to Model Neuro-Immune-Endocrine Disorders

  2024cites this paper
• Single-cell pathogen diagnostics for combating antibiotic resistance

  2023cites this paper
• Why to Study Peptides from Venomous and Poisonous Animals?

  2023cites this paper
• Synthesis and biological evaluation of ruthenium complexes bearing the 1,2,4-triazole group as potential membrane-targeting antibacterial agents towards Staphylococcus aureus.

  2023cites this paper
• Recent Approaches for Downplaying Antibiotic Resistance: Molecular Mechanisms

  2023cites this paper
• Pseudomonas aeruginosa: Infections, Animal Modeling, and Therapeutics

  2023cites this paper
• Managing interorganizational interactions for social impact: A study of two antibiotics R&D networks

  2022cites this paper
• Targeted Protein Degradation for Infectious Diseases: from Basic Biology to Drug Discovery

  2022cites this paper
• Coumarin-1,2,3-triazole hybrids as leading-edge anticancer agents

  2022cites this paper
• Discovery of a fragment hit compound targeting D-Ala:D-Ala ligase of bacterial peptidoglycan biosynthesis

  2022cites this paper
• An Ambitious USG Advanced Commitment for Subscription-Based Purchasing of Novel Antimicrobials and Its Expected Return on Investment

  2022cites this paper
• Applying the resource interaction approach to policy analysis – Insights from the antibiotic resistance challenge

  2022cites this paper
• In vitro research of combination therapy for multidrug-resistant Klebsiella pneumoniae bloodstream infections

  2022cites this paper
• Combinatorial nanodroplet platform for screening antibiotic combinations.

  2022cites this paper
• Analysis of the Clinical Pipeline of Treatments for Drug-Resistant Bacterial Infections: Despite Progress, More Action Is Needed

  2022cites this paper
• A Clinical Trial to Evaluate the Efficacy of α-Viniferin in Staphylococcus aureus – Specific Decolonization without Depleting the Normal Microbiota of Nares

  2021cites this paper
• Molecular descriptor analysis of approved drugs using unsupervised learning for drug repurposing

  2021cites this paper
• Population Pharmacokinetics and Pharmacodynamics of Meropenem in Critically Ill Patients: How to Achieve Best Dosage Regimen According to the Clinical Situation

  2021cites this paper
• Targeting the bacterial SOS response for new antimicrobial agents: drug targets, molecular mechanisms and inhibitors.

  2021cites this paper
• U.S. FDA Approved Drugs from 2015-June 2020: A Perspective.

  2021cites this paper
• Nanotechnology approaches for global infectious diseases

  2021cites this paper
• FDA‐Approved Medicines

  2021cites this paper
• Catalytic antimicrobial therapy using nanozymes.

  2021cites this paper
• Antibacterial R&D at a crossroads: We've pushed as hard as we can … now we need to start pulling!

  2020cites this paper
• Ferrocenyl chalcone derivatives as possible antimicrobial agents

  2020cites this paper
• Predicting antimicrobial resistance in Pseudomonas aeruginosa with machine learning‐enabled molecular diagnostics

  2020cites this paper
• Synthesis of novel 3-[(2R*)-2-[(2S*)-6-fluoro-3,4-dihydro-2H-chromen-2-yl]-2-hydroxyethyl]-urea/thiourea derivatives and evaluation of their antimicrobial activities

  2020cites this paper
• Ontology, difference, and the antimicrobial resistance timeline

  2020cites this paper
• Identification of the natural product paeonol derived from peony bark as an inhibitor of the Salmonella enterica serovar Typhimurium type III secretion system

  2020cites this paper
• Trends in Drug Discovery over Five Decades – The European Federation for Medicinal Chemistry International Symposium on Medicinal Chemistry (EFMC−ISMC)

  2020cites this paper
• Preliminary view of the global distribution and spread of the tet(X) family of tigecycline resistance genes.

  2020cites this paper
• PROPHETIC: Prospective Identification of Pneumonia in Hospitalized Patients in the Intensive Care Unit.

  2020cites this paper
• The microbiome: a reservoir to discover new antimicrobials agents.

  2020cites this paper
• Time-constrained interactions in public-private collaboration projects. The case of ENABLE

  2020cites this paper
• Evaluation of burn wound healing activity of novel fusidic acid loaded microemulsion based gel in male Wistar albino rats

  2020cites this paper
• NfsB quickly reduces chloramphenicol to amino-chloramphenicol in vitro d Metronidazole potentiates chloramphenicol activity against nitro reducing

  2019cites this paper
• Spirocyclic tetramates by sequential Knoevenagel and [1,5]-prototropic shift.

  2019cites this paper
• Bacteriophage versus antibiotic therapy on gut bacterial communities of juvenile green turtle, Chelonia mydas.

  2019cites this paper
• Evaluation of the published kinase inhibitor set to identify multiple inhibitors of bacterial ATP-dependent mur ligases

  2019cites this paper
• Discovery and Characterization of a Nitroreductase Capable of Conferring Bacterial Resistance to Chloramphenicol.

  2019cites this paper
• Tigecycline in combination with other antibiotics against clinical isolates of carbapenem-resistant Klebsiella pneumoniae in vitro.

  2019cites this paper
• Bioguided identification of antimicrobial compounds from Chrysopogon zizaniodes (L.) Roberty root essential oil.

  2019cites this paper
• AR Mechanism‐Based Drug Design

  2019cites this paper
• Preparation and evaluation of QbD based fusidic acid loaded in situ gel formulations for burn wound treatment

  2019cites this paper
• Identification of a potent small-molecule inhibitor of bacterial DNA repair that potentiates quinolone antibiotic activity in methicillin-resistant Staphylococcus aureus☆

  2019cites this paper
• Increase Development and Decrease Use! Innovation Controversies Caused by Antimicrobial Resistance

  2018cites this paper
• Data Sets Representative of the Structures and Experimental Properties of FDA-Approved Drugs.

  2018cites this paper
• Insights into early stage of antibiotic development in small- and medium-sized enterprises: a survey of targets, costs, and durations

  2018cites this paper
• Discovery and Optimization of Indolyl-Containing 4-Hydroxy-2-Pyridone Type II DNA Topoisomerase Inhibitors Active against Multidrug Resistant Gram-negative Bacteria

  2018cites this paper
• Burn injury: Challenges and advances in burn wound healing, infection, pain and scarring

  2018cites this paper
• Elucidating the bactericidal mechanism of action of the linear antimicrobial tetrapeptide BRBR-NH2.

  2018cites this paper
• Radiopharmaceutical enhancement by drug delivery systems: A review

  2018cites this paper
• Introduction and geographic availability of new antibiotics approved between 1999 and 2014

  2018cites this paper
• Fire in the Forest: Adverse Effects of Antibiotics on the Healthy Human Gut Microbiome

  2018cites this paper
• New Drug Approvals by FDA from 2013-2017

  2018cites this paper
• Small at Size, Big at Impact: Microorganisms for Sustainable Development

  2018cites this paper
• The Decline of Innovation in the Antibiotics Industry and the Global Threat of Antibiotic Resistance: When Entrepreneurial Efforts are Not Enough

  2018cites this paper
• Pheroid℗ technology as a tool to change the administration route of selected pharmaceuticals from intravenous to oral

  2018cites this paper
• Innovative payer engagement strategies: will the convergence lead to better value creation in personalized medicine?

  2017cites this paper
• 4-Hydroxy-2-pyridones: Discovery and evaluation of a novel class of antibacterial agents targeting DNA synthesis.

  2017cites this paper
• Discovery and Total Synthesis of Natural Cystobactamid Derivatives with Superior Activity against Gram-Negative Pathogens.

  2017cites this paper
• Plasticity, dynamics, and inhibition of emerging tetracycline-resistance enzymes

  2017cites this paper
• Entdeckung und Totalsynthese von natürlichen Cystobactamid‐Derivaten mit herausragender Aktivität gegen Gram‐negative Pathogene

  2017cites this paper
• The Story of Kinase Inhibitors Development with Special Reference to Allosteric Site

  2017cites this paper
• Antifungal peptides: a potential new class of antifungals for treating vulvovaginal candidiasis caused by fluconazole‐resistant Candida albicans

  2017cites this paper
• Screening for a Potent Antibacterial Peptide to Treat Mupirocin-Resistant MRSA Skin Infections

  2017cites this paper
• Mimics of pramanicin derived from pyroglutamic acid and their antibacterial activity.

  2017cites this paper
• Bacteriophage Clinical Use as Antibacterial “Drugs”: Utility and Precedent

  2017cites this paper
• Genomic and functional techniques to mine the microbiome for novel antimicrobials and antimicrobial resistance genes

  2017cites this paper
• Repurposing Zidovudine in combination with Tigecycline for treating carbapenem-resistant Enterobacteriaceae infections

  2017cites this paper
• Compound design guidelines for evading the efflux and permeation barriers of Escherichia coli with the oxazolidinone class of antibacterials: Test case for a general approach to improving whole cell Gram-negative activity.

  2017cites this paper
• Antibacterial New Target Discovery: Sentinel Examples, Strategies, and Surveying Success

  2017cites this paper
• Synthesis and antibacterial activity of new symmetric polyoxygenated dibenzofurans.

  2017cites this paper
• An analysis of FDA-approved drugs for cardiovascular diseases.

  2016cites this paper
• Hybrid antibiotics – clinical progress and novel designs

  2016cites this paper
• The origin of FDA approved natural product new chemical entities

  2016cites this paper
• Protecting human security: proposals for the G7 Ise-Shima Summit in Japan.

  2016cites this paper
• An analysis of FDA-approved drugs: natural products and their derivatives.

  2016cites this paper
• New antibiotics from Nature's chemical inventory.

  2016cites this paper
• Pyroptosis of Salmonella Typhimurium-infected macrophages was suppressed and elimination of intracellular bacteria from macrophages was promoted by blocking QseC

  2016cites this paper
• The effects of antibiotics on the microbiome throughout development and alternative approaches for therapeutic modulation

  2016cites this paper
• Exploring the Obstacles to Implementing Economic Mechanisms to Stimulate Antibiotic Research and Development

  2016cites this paper
• Natural Products as a Source for Novel Antibiotics.

  2016cites this paper
• Antibiotic reimbursement in a model delinked from sales: a benchmark-based worldwide approach.

  2016cites this paper
• A history of drug development in four acts.

  2015cites this paper
• One cannot rule them all: Are bacterial toxins-antitoxins druggable?

  2015cites this paper
• Cell-based bioluminescent high-throughput screening methods in antibacterial drug discovery

  2015cites this paper
• Target selection for FDA-approved medicines.

  2015influential citation
• Development of new antibiotics: taking off finally?

  2015cites this paper
• Synthesis of Medicinally Relevant Thiazolyl Aryl Ketones Under Mild Conditions

  2015cites this paper
• Attrition in Drug Discovery and Development

  2015cites this paper
• Equisetin, reutericyclin and streptolodygin as natural product lead structures for novel antibiotic libraries.

  2015cites this paper